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To the Editor: Cutaneous leishmaniasis (CL) is a pro-
tozoan disease transmitted by sand flies that usually runs 
a relatively mild course. Classic CL starts as a red papule 
at the place of the insect bite; it gradually enlarges into a 
painless nodule or plaque-like lesion, which eventually be-
comes encrusted. When the crust falls off, a typical ulcer 
with raised and indurated border becomes apparent. CL can 
cause considerable illness and may leave disfiguring and 
disabling scars after healing. The interplay between Leish-
mania species and host immune response is complex, and, 
as a result, disease manifestations may vary substantially 
among species as well as among infected persons (1,2). An 
estimated 0.7–1.2 million new CL cases occur annually in 
tropical and subtropical regions of the world. CL is cur-
rently endemic in >98 countries worldwide; Afghanistan, 
Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Su-
dan, Costa Rica, and Peru together account for up to 75% 
of global estimated CL incidence (3).
We report 3 travel companions from the Netherlands 
who all acquired CL after they participated in a short-term 
study course in Israel during September–October 2015. 
The travelers visited several places in the Negev Desert in 
southern Israel. All cases were confirmed by PCR with ad-
ditional sequence analysis of the mini-exon locus and the 3′ 
untranslated region of the HSP70 locus, demonstrating L. 
major as the causative species (4).
The first case-patient was a 55-year-old man who ob-
served red papules on his head and shoulder 1 month after 
he returned to the Netherlands. Gradually, these papules 
increased in size, and number and showed a tendency to 
ulcerate. On examination at the Institute for Tropical Dis-
eases in Rotterdam, 12 painless, hyperkeratotic, plaquelike, 
sharply demarcated lesions were identified, some partially 
ulcerated, located on the head, shoulders, arms, legs, and 
across the chest. Histopathologic examination on skin bi-
opsy specimens acquired from 1 lesion revealed Leishma-
nia amastigotes, consistent with a diagnosis of CL. The pa-
tient was treated with miltefosine (50 mg orally 3×/d for 28 
d). Clinical recovery followed gradually.
The second case-patient, a 52-year-old woman, noticed 
some red papules on both legs that gradually increased in 
size and ulcerated in the 2 months after return to the Neth-
erlands. She was initially treated by a general practitioner 
for a presumed bacterial skin infection but did not show a 
clinical response to antibiotic treatment. On examination, 
also at the Institute for Tropical Diseases, 6 painless ulcers 
were seen on her legs. CL was suspected after taking into 
account the clinical manifestations and the recent diagno-
sis of CL in her travel companion. She was successfully 
treated with miltefosine after the diagnosis was confirmed.
A third case-patient, a 52-year-old woman, was diag-
nosed with CL after she sought treatment for a single small, 
sharply demarcated, painless pretibial plaquelike skin le-
sion on her arm that had been present for 2 months after her 
return to the Netherlands. Repeated PCRs of skin biopsy 
specimens confirmed the diagnosis of L. major CL. She 
preferred a “wait and see” policy over treatment.
The 3 patients with CL, a cluster of travel companions, 
were conceivably infected in the Negev Desert. Only 1 pre-
vious report has documented a traveler returning from Isra-
el who was diagnosed with CL at the Institute for Tropical 
Diseases during 2007–2016 (Table). Most cases originated 
from the New World, in particular from South America, 
followed by Central America (Table). Few of these cases 
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originated from the Old World, where most of the global ef-
fects of CL occur. CL is more frequently diagnosed among 
long-term travelers such as military personnel, adven-
ture travelers, photographers, and researchers, rather than 
among short-term travelers (5).
Recent reports have described a 7-fold increase in 
L. major CL cases among inhabitants of the Negev Des-
ert (6), with urban expansion into CL-endemic foci and 
changes in land use currently regarded as the most prob-
able causes for this increase in incidence (6,7). A concur-
rent increase among travelers has not occurred so far, al-
though the aforementioned cases might indicate that the 
increasing risk of contracting CL in the Negev Desert is 
not only restricted to its inhabitants but may also pose a 
risk to short-term travelers.
The spectrum of disease of CL is highly variable, even 
among persons infected with the same Leishmania species 
(1,2,8), as illustrated by this cluster of L. major CL cases 
among persons who traveled together to Israel. Because L. 
major CL might mimic other infectious and inflammatory 
diseases, physicians assessing travelers with painless and 
persistent skin ulcers after their return from CL-endemic 
countries should therefore consider CL in their differen-
tial diagnosis. In conclusion, awareness should be raised 
among physicians and healthcare workers that CL is not 
exclusively limited to tropical countries but may also be 
acquired by short-term travelers to more temperate regions, 
such as southern Europe and the Levant (Syria, Lebanon, 
Israel, and Jordan) (3,9).
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Table. Characteristics of 3 travel companions to Israel and a cohort of patients with imported cutaneous leishmaniasis previously 
diagnosed at the Institute for Tropical Diseases, Harbour Hospital, Rotterdam, the Netherlands, 2007–2016 
Characteristics Case-patient 1 Case-patient 2 Case-patient 3 Cohort, n = 27* 
Age, y (SD) 55.2 52.6 52.3 45.4 (15.2) 
Sex M F F M: 19 (70.4); F: 8 (29.6) 
New World/Old World Old World Old World Old World New World: 18 (66.7); Old World: 9 (33.3) 
Country of acquisition  Israel Israel Israel Argentina: 1 (3.7); Brazil; 2 (7.4); Costa Rica: 
2 (7.4); Ecuador: 3 (11.1); Ethiopia: 1 (3.7); 
French-Guyana: 1 (3.7); Israel: 1 (3.7); 
Mexico: 1 (3.7); Morocco: 4 (14.8); Peru: 1 
(3.7); Spain: 2 (7.4); Suriname: 6 (22.2); 
Trinidad and Tobago: 1 (3.7); Turkey: 1 (3.7) 
Reason for visit  Tourism Tourism Tourism Tourism: 18 (66.7); work-related visit: 2 (7.4); 
family visit: 6 (22.2); unknown: 1 (3.4) 
Clinical manifestation  Ulceration/plaque-
like lesion 
Ulceration Plaque-like lesion Erythematous papule: 1 (3.7); 
nodule/plaquelike lesion: 9 (33.3); ulceration: 
17 (63.0) 
Mean no. skin lesions 12 6 1 1.6 (median 1.0, range 1.0–5.0) 
Localization ≥1 localization ≥1 localization Lower leg Face: 4 (14.8); upper arm: 3 (11.1); lower 
arm: 10 (37.0); upper leg: 0; lower leg: 6 
(22.2); trunk or neck: 1 (3.7); ≥1 localization: 
3 (11.1) 
Diagnostic method  Histology/PCR Histology/PCR Histology/PCR Histology: 0; PCR: 19 (70.3); histology/PCR: 
8 (29.7) 
Leishmania spp. L. major L. major L. major L. major: 2 (7.4); L. tropica: 1 (3.7); L. 
infantum: 4 (14.8); L. donovani: 1 (3.7); L. 
mexicana: 1 (3.7); L .braziliensis: 7 (25.9); L. 
guyanensis: 4 (14.8); L. panamensis: 1 (3.7); 
L. lainsoni: 1 (3.7); Unknown: 5 (18.5) 
Treatment Miltefosine Miltefosine Wait and see Cryotherapy: 2 (7.4); topical 
paromomycin/methylbenzethoniumchloride: 1 
(3.7); theurapeutic excision: 1 (3.7); 
fluconazole: 1 (3.7); pentamidineisethionate: 
2 (7.4); systemic stibogluconate: 3 (11.1); 
miltefosine: 17 (63.0) 
*Values are no. (%) except as indicated. 
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To the Editor: Norovirus is the world’s leading cause 
of nonbacterial acute gastroenteritis (1). Since their emer-
gence, GII.P17-GII.17 noroviruses have replaced the GII.4 
Sydney 2012 variant as the dominating norovirus genotype 
in parts of Asia (2), although they have been detected only 
sporadically, in a limited number, on other continents (3).
The major reservoir(s) of GII.17 that contribute to 
transmission are unknown, but it has been suggested that 
oysters and other bivalve shellfish are common vehicles 
for transmission of the emerging GII.17 viruses (2). In this 
study, we demonstrate the link between oysters and human 
disease by presenting molecular evidence of norovirus GII.
P17-GII.17 in Denmark causing acute gastroenteritis, char-
acterized by the sudden onset of vomiting with or without 
diarrhea after consumption of oysters. We further document 
molecular evidence providing linkage between norovirus 
detected in fecal samples from patients and food samples 
from imported oysters.
During January 23–February 4, 2016, acute gastroen-
teritis developed in 58 of 67 persons who consumed oysters 
served on 18 separate occasions at 8 different restaurants 
and a private party, with onset of symptoms within 24–40 
hours after the patients ate oysters. All oysters originated 
from 2 distinct oyster lots provided by 1 wholesaler in 
France and distributed by 1 wholesaler in Denmark. Oys-
ters from both lots were harvested off the coast of La Ro-
chelle, France.
In Denmark, submitting fecal samples in connection 
with foodborne outbreaks is voluntary. A total of 5 samples 
from 3 cases representing 2 different parties were submit-
ted to the National Virus Surveillance Laboratory at Stat-
ens Serum Institut (Copenhagen, Denmark) for norovirus 
analysis. In addition, 4 samples of oysters from the same 
producer in France were sent to the National Food Insti-
tute, Technical University of Denmark (Kongens Lyngby, 
Denmark), for norovirus analysis. Two samples, an opened 
(sample A) box and an unopened (sample B) box collected 
at one of the restaurants involved in the outbreak, contained 
oysters from 1 batch (I), and another 2 samples (C and D) 
contained oysters from a separate batch (II) collected at the 
wholesale level.
Norovirus in fecal samples was detected and polymerase 
(open reading frame [ORF]1) and capsid (ORF2) gene re-
gions were amplified as described elsewhere (4). Sequenc-
ing was performed by using an ABI 3500 genetic analyzer 
(Thermo Fisher Scientific, Nærum, Denmark). A fragment of 
1,111 nt spanning the ORF1–ORF2 junction was amplified 
and sequenced by using forward ORF1 primer JV12 and re-
verse ORF2 primer G2SKR (4). Genotyping was performed 
by using the Web-based norovirus typing tool NoroNet 
(http://www.rivm.nl/mpf/norovirus/typingtool) (5).
We found that all fecal samples contained norovirus 
belonging to genogroup II (GII). Sequencing of the poly-
merase region was successful in 4 of the 5 samples; all 5 
samples were sequenced in the capsid region. Typing of 
the sequences indicated GII.P17 and GII.17, respectively. 
Furthermore, PCR and sequencing of the long fragment 
covering the ORF1–ORF2 junction were successful in 2 
samples, both genotyping as GII.P17-GII.17. Sequences 
had high homology (99.91%) to several Asian strains, such 
as Hu/GII.P17_GII.17/KR/2014/CAU-265 (6).
Oysters were analyzed for norovirus (7), and the capsid 
region of the detected strains was sequenced (8). Samples 
A, B, and C contained norovirus GI, whereas all 4 samples 
(A–D) contained norovirus GII. GI.2 was identified in 1 
sample (B), and GII.17 was identified in all samples (A–D). 
The GII.17 sequences obtained from samples A–C showed 
100% homology, whereas the sequence identified in sam-
ple D varied at 3 positions.
Comparisons of the capsid sequences obtained from 
4 human samples and oyster samples A–C showed 100% 
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